Medicines	Indication	Further Information	Estimated LSCMMG		
New Medicine Reviews for December LSCMMG meeting					
Triptorelin	Treatment of precocious puberty	Requested by Medicines Management, Fylde Coast locality	December 2023		
Actimorph	Severe pain and breathlessness in patients with symptoms due to a palliative (life limiting) illness	Requested by LTHTr	December 2023		
Symbicort	As a reliever therapy for mild asthma (SPC change)	Requested by ICB respiratory group	December 2023		
Medicines prioritised for New Medicine Reviews - for future LSCMMG meeting					
Fluorides	Prophylaxis of dental caries	Requested by Medicines Management, Fylde Coast locality	January 2024		
Bempedoic acid monotherapy	For treating primary hypercholesterolaemia or mixed dyslipidaemia + RAG rating review for combination with ezetimibe	Requested by Medicines Management, Central locality	January 2024		
Qutenza 179mg cutaneous patch (capsaicin)	Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain	Requested by Pain Management Consultant, Blackpool Teaching Hospitals Trust	February 2024		
Navina Smart	Trans anal irrigation system	Requested by Medicines Management, Fylde Coast locality	February 2024		
Acarizax 12 SQ-HDM oral lyophilisate	Treatment of house dust mite sensitisation according to SPC definitions, see: <a href="https://www.medicines.org.uk/emc/product/12905">https://www.medicines.org.uk/emc/product/12905</a>	Requested by ENT consultant, ELHT	March 2024		

Liothyronine oral preparations	Treatment of resistant depression – reclassification from Do not prescribe to Amber 1	Requested by Lancashire and South Cumbria NHS Foundation Trust	April 2024	
Colesevelam	For CVD prevention in hyperlipidaemia when the patient is intolerant of all other options	Requested by Medicines Management, Central ICB locality	April 2024	
Nefopam	Treatment of pain	Pharmacy, BTHTr	April 2024	
Ivabradine	Treatment of POTS (postural orthostatic tachycardia syndrome)	Cardiologist, BTHTr	May 2024	
Infliximab	For treatment of chemotherapy induced colitis	Requested by Oncology Pharmacist UHMB	May 2024	
GoResp digihaler (budesonide/formoterol)	For treatment of asthma and COPD	Requested by Medicines Management, Fylde Coast	June 2024	
Medicine on hold, awaiting licensing or additional information				
Infliximab increased dosing	Treatment of ulcerative colitis and Crohn's disease	Requested by ELHT. Awaiting pathway discussions before proceeding.	TBC	